Pure Global
NCT05914467

TDM-optimized Teicoplanin Dosing Versus Standard of Care

A Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of Care
Radboud University Medical Center·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bacterial Infections
Drug/Device/Intervention
Teicoplanin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Radboud University Medical Center
Timeline & enrollment
Phase
Phase 4
Start date
Jul 01, 2023
End date
Dec 30, 2024
Enrollment
74 participants
Primary outcome

Fraction of participants that reaches therapeutic exposure after 5 days of treatment

Summary

Value of TDM for teicoplanin is not well defined. In this single-center low-interventional
 randomized trial the investigators aim to investigate the superiority of teicoplanin
 TDM-optimized using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus
 the standard of care (dosing based on antibiotic guidelines) in target attainment.

ICD-10 classifications
Bacterial infection, unspecifiedBacterial, viral and other infectious agentsOther bacterial intestinal infectionsOther bacterial diseasesOther specified bacterial intestinal infections
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05914467
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05914467 through Pure Global AI's free database. This Phase 4 trial is sponsored by Radboud University Medical Center and is currently Not yet recruiting. The study focuses on Bacterial Infections. Target enrollment is 74 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.